Others have investigated the application of amniotic stem cells in cardiomyopathy. Yeh et al. first evaluated human amniotic fluid-derived stem cells to determine if these cells had the capability to give rise to cardiac as well as endothelial cells in vitro. Next they created an experimental infarction in a rat model and injected the cells directly into the peri-infarct areas. The results indicated that the injected cells survived and proliferated at the injured site and promoted attenuation of left ventricular remodeling, a higher vascular density, and thus an improvement in cardiac function (80 ).
In other words, the injected cells grew new heart tissue and the patient no longer needed medication.
In the most simple and plain fact language and terms. Heart disease is not a small subject and neither is the condition, but like any organ, in this case a muscle it can re-grow. Amniotic Stem Cells provide the necessary 8 Stem Cell Factors to regrow and organ as they have all of the coding to regrow a human in the womb. It makes clear sense that an IV drip of the cells that build the heart would know the pathway to accelerated healing in order to reduce the medications that seem to help, but feel more a limitation.
Stem cells unchain the limits of heart healing and help to re-condition the human heart and give it a much needed tune up.